Replies to post #245553 on Biotech Values

[DewDiligence]

APLS PR on FDA approval of Syfove:

https://www.globenewswire.com/news-release/2023/02/17/2610967/0/en/FDA-Approves-SYFOVRE-pegcetacoplan-injection-as-the-First-and-Only-Treatment-for-Geographic-Atrophy-GA-a-Leading-Cause-of-Blindness.html

Syfovre label: https://t.co/s3AYAaaxLc

p.s. The "fov" in the brand name, Syfovre presumably derives from the fovea.

[DewDiligence]

A mostly bearish take on APLS’ Syfovre:

https://www.biopharmadive.com/news/apellis-fda-approval-syfovre-geographic-atrophy/643111/